

ARVO 2022

---

# View Abstract

---


**CONTROL ID:** 3706106**SUBMISSION ROLE:** Abstract Submission**AUTHORS****AUTHORS (LAST NAME, FIRST NAME):** [Salzmann, Simon](#)<sup>1</sup>; Burri, Christian<sup>1, 2</sup>; Al-Nawaiseh, Sami<sup>3</sup>; Wakili, Philip<sup>4</sup>; Meier, Christoph<sup>1</sup>**INSTITUTIONS (ALL):** 1. HuCE optoLab, Berner Fachhochschule, Biel, Switzerland.

2. Institute of Applied Physics – Biomedical Photonics Group, Universitat Bern, Bern, Switzerland.

3. Department of Ophthalmology, Universitätsklinikum Munster, Munster, Germany.

4. Eye Clinic Sulzbach, Knappschaftsklinikum Saar GmbH Krankenhaus Sulzbach, Sulzbach, Germany.

**Commercial Relationships Disclosure:** Simon Salzmann: Commercial Relationship(s);Code F (Financial Support):Heidelberg Engineering, Meridian Medical;Code R (Recipient):Heidelberg Engineering, Meridian Medical, Haag-Streit | Christian Burri: Commercial Relationship(s);Code F (Financial Support):Heidelberg Engineering, Meridian Medical;Code R (Recipient):Heidelberg Engineering, Meridian Medical, Haag-Streit | Sami Al-Nawaiseh: Commercial Relationship(s);Code R (Recipient):Heidelberg Engineering | Philip Wakili: Commercial Relationship: Code N (No Commercial Relationship) | Christoph Meier: Commercial Relationship: Code N (No Commercial Relationship)**Study Group:** (none)**ABSTRACT****TITLE:** Optical Coherence Tomography Navigated Laser Retinopexy for Retinal Breaks**ABSTRACT BODY:****Purpose:** The prevalent cause of retinal detachment is a full-thickness retinal break, which allows fluid to enter the subretinal space from the vitreous cavity. To prevent progression of the detachment, laser photocoagulation (LPC) lesions are placed around the break in clinical practice to seal the tissue. The treatment is usually performed under indirect ophthalmoscopy. Therefore, the subretinal damage can be difficult to delineate and an experienced operator is required for a successful outcome. In this work, optical coherence tomography (OCT) is used for optimal treatment planning, and LPC is subsequently applied in a navigated and user-friendly procedure.**Methods:** The novel method was integrated in a modified OCT diagnostic system (SPECTRALIS OCT, Heidelberg Engineering, Heidelberg, Germany) with integrated treatment laser (Merilas 532 shortpulse, Meridian, Thun, Switzerland). To reliably seal the break, LPC lesions must be applied in regions of still attached retina. Therefore, OCT B-scans were used to manually mark the boundary of the surrounding detachment, which allowed to compute an optimally placed elliptical treatment area. To evaluate the method, artificially provoked retinal breaks were treated accordingly in 10 ex-vivo porcine eyes and the outcome was assessed by fundus photography and OCT imaging.**Results:** Ex-vivo experiments showed that OCT-based laser treatment is feasible and the visibility of the subretinal space allows precise treatment planning. A total of 99 to 227 automatically applied lesions per eye at 200 ms and 200 mW were evident as coagulation in color fundus photography. Furthermore, OCT cross-sectional scans showed the required ruptures of the retina at the LPC application sites (Figure 1).**Conclusions:** The results indicate the potential of OCT navigated laser retinopexy to achieve high treatment accuracy, efficiency, and safety. Future studies should address treatment of peripheral breaks and the integration of the existing tracking and follow-up functionalities to further enhance and facilitate the treatment.



Retinal break treatment outcome in an ex-vivo porcine eye. Fundus photographs before (A) and after (B) treatment, infrared scanning laser ophthalmoscope images before (C) and after (E) treatment with the corresponding OCT B-scans (D)(F). The effect of LPC treatment is visible in (B)(E) as spots of whitened tissue and in (F) as ruptures in the retina at the treatment sites (marked in red).

### **DETAILS**

**PRESENTATION TYPE:** Poster Only

**CURRENT REVIEWING CODE:** 2630 Laser - RE

**CURRENT SECTION:** Retina

**Clinical Trial Registration (Abstract):** No

**Other Registry Site (Abstract):** (none)

**Registration Number (Abstract):** (none)

**Date Trial was Registered (MM/DD/YYYY) (Abstract):** (none)

**Date Trial Began (MM/DD/YYYY) (Abstract):** (none)

**Grant Support (Abstract):** No

**Support Detail (Abstract):** None

### **TRAVEL GRANTS and AWARDS APPLICATIONS**

**AWARDS:** ARVO and ARVO Foundation Travel Grants

---

© Clarivate Analytics | © ScholarOne, Inc., 2022. All Rights Reserved.

ScholarOne Abstracts and ScholarOne are registered trademarks of ScholarOne, Inc.

ScholarOne Abstracts Patents #7,257,767 and #7,263,655.

[@ScholarOneNews](#) | [System Requirements](#) | [Privacy Statement](#) | [Terms of Use](#)

Product version number 4.17.4 (Build 127). Build date Mon Dec 13 07:31:22 EST 2021. Server ip-10-236-29-34